Metastatic breast cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,062 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

  NCT04517838· Mayo Clinic· Updated 9 Nov 2026

  “Insufficient funding to complete target accrual”Registry text, quoted unchanged. Source

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Swiss Cancer Institute· Updated 23 Oct 2026

  “Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication”Registry text, quoted unchanged. Source

• Terminated

  Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

  NCT05335473· Henan Cancer Hospital· Updated 16 Oct 2026

  “The anticipated efficacy was not achieved; the primary objective of Stage 1 in the Simon-2 design was not met.”Registry text, quoted unchanged. Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· UNICANCER· Updated 14 Oct 2026

  “poor accrual”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  NCT06568692· Processa Pharmaceuticals· Updated 6 Oct 2026

  “Business Reason”Registry text, quoted unchanged. Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Updated 29 Sept 2026

  “The study was terminated prematurely due to insufficient patient recruitment.”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

• Terminated

  Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

  NCT04315233· University of Utah· Updated 4 Sept 2026

  “No accrual in one year”Registry text, quoted unchanged. Source

• Terminated

  Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05756166· Roswell Park Cancer Institute· Updated 31 Aug 2026

  “Funding ended”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

  NCT07619534· National Cancer Institute (NCI)· Source

• Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and/or Platinum Chemotherapy

  NCT07864792· University of Michigan Rogel Cancer Center· Source

• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

  NCT04222413· National Cancer Institute (NCI)· Source

• BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· BeOne Medicines I GmbH· Source

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  NCT03424005· Hoffmann-La Roche· Source

• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Hoffmann-La Roche· Source

• A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

  NCT02297438· Pfizer· Source

• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

  NCT03606967· National Cancer Institute (NCI)· Source

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 19
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 62
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 69
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• Machine learning for predicting mortality in women diagnosed with breast cancer in the State of Mato Grosso, Brazil using linked population-based cancer registry and mortality data.

  PLoS One, Sept 2026

• Machine Learning Comparison and Combined Model Optimization Based on DCE-MRI Radiomics for Preoperative Assessment of Lymphovascular Invasion in Breast Cancer: A Multicenter Study.

  Cancer Rep (Hoboken), Sept 2026

• Performance of Statistical and Machine Learning Risk Prediction Models for Advanced Breast Cancer.

  Cancer Epidemiol Biomarkers Prev, Aug 2026

• Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study.

  Breast Cancer Res Treat, Jul 2026

• Machine Learning Classification of Axillary Lymph Nodes Using Microwave Signals.

  Sensors (Basel), Jul 2026

• Development and validation of a prognostic model for stage IV breast cancer based on primary tumor resection with machine learning methods: retrospective cohort study.

  Front Endocrinol (Lausanne), Jul 2026

• Predicting sentinel lymph node metastasis in breast cancer using an interpretable machine learning approach based on multi-domain clinical features.

  Breast Cancer Res, Jul 2026

• A predictive model for pathological complete response in neoadjuvant-treated breast cancer: integrating pretreatment clinicopathologic and contrast-enhanced ultrasound characteristics via interpretable machine learning.

  BMC Cancer, Jul 2026

• Machine learning prediction of axillary lymph node metastasis using multimodal ultrasound in breast cancer.

  Future Oncol, Jun 2026

• Use of contrast-enhanced mammography for preoperative prediction of lymphovascular invasion status in invasive breast cancer.

  Cancer Imaging, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.